Physician profile
Camilo Tabora
NPI 1265543458
$7,955.99
in general payments reported to CMS, 2019-2025
39 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $961 · 2021: $1,374 · 2022: $1,839 · 2023: $1,268 · 2024: $1,141 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,820.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,634.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $891.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $731.47 | 2019-2025 | |
| Amgen INC. | $623.24 | 2019-2024 | Repatha, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $447.39 | 2019-2025 | Pediarix, Bexsero, Shingrix |
| Merck Sharp & Dohme LLC | $409.24 | 2019-2025 | Verquvo, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $383.32 | 2022-2023 | |
| Amarin Pharma, INC. | $363.78 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.66 | 2020-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $280.26 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.88 | 2019-2024 | Jardiance |
| Ibsa Pharma INC. | $162.43 | 2022 | |
| Abbvie INC. | $144.18 | 2022-2025 | |
| Abbott Laboratories | $140.03 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Horizon Therapeutics Plc | $131.35 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camilo Tabora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.